Venture&Growth Archives - Gilde Healthcare

Menu
Menu
Home

latest news
Venture&Growth

Gilde Healthcare closes new Venture&Growth fund at €740 million hard cap

Gilde Healthcare Venture&Growth VI closes at its hard cap with €740 million from a balanced mix of international investors Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its dedicated Impact Council In three years’ time, Gilde Healthcare raised €1.7 billion across three funds Gilde Healthcare today announces the final close of its...
November 15, 2023

Gilde Healthcare company SpliceBio enters $216 million Gene Therapy collaboration with Spark Therapeutics

test SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio’s proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy targeting an undisclosed inherited retinal disease SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of […]

Gilde Healthcare company AM-Pharma announces positive clinical data from Phase 1b study evaluating ilofotase alfa in hypophosphatasia patients

test AM-Pharma B.V. today announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacement therapy in adult hypophosphatasia (HPP) patients. HPP is an inherited metabolic disease, characterized by low activity of tissue non-specific alkaline phosphatase (TNAP), caused by mutations at the ALPL gene. This […]

Gilde Healthcare company Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces it has achieved the first milestone in the second active discovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY), triggering a payment for...

Gilde Healthcare company AM-Pharma announces updated clinical development strategy

Advancing ilofotase alfa into a Phase 2 study for lead indication cardiac surgery-associated renal damage Phase 1b study of ilofotase alfa as enzyme replacement therapy in hypophosphatasia patients being finalized, results to be announced before end of 2023 Juliane Bernholz, AM-Pharma’s Chief Operating Officer since 2019, succeeds...

Gilde Healthcare company Moximed reports treatment of first commercial patients post FDA approval

Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement Multiple surgeons from multiple U.S. centers treat patients with knee osteoarthritis

Gilde Healthcare company Withings launches its next-generation scanwatch with enhanced sensors to monitor additional health metrics 24/7

Withings introduces the hybrid watch that watches your health day and night with new capabilities to monitor body temperature 24/7, heart rate variability, respiratory rate and female menstrual cycles

Gilde Healthcare company Big Health expands into adolescent mental health through acquisition of Limbix

Big Health, the leading provider of non-drug digital treatments for mental health, has acquired Limbix, creators of the first, evidence-based digital therapeutic for teens and young adults with symptoms of depression. Since its founding in 2016, Limbix has raised $30 million and has built a research-based pipeline...

Volta Medical Announces Initiation of RESTART Clinical Trial for Treatment of Repeat Atrial Fibrillation

Interventional study to evaluate long term outcomes of Volta’s AI solution-supported ablation in recurrent-AF patients who failed previous ablation International, multi-center trial at 21 sites with results expected in 2025 Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists in treating...
Loading...
These were all messages
0bf2acf945